Corvus Pharma Q3 EPS $(0.22), Inline

Benzinga · 11h ago
Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.22) per share which met the analyst consensus estimate. This is a 83.33 percent decrease over losses of $(0.12) per share from the same period last year.